Dobi Medical Systems and United Telecoms Ltd, India have
signed a deal wherein UTL will sell the ComfortScan of Dobi Medical in India. According to the press release, UTL has agreed to buy 40 ComfortScan machines in the next 18 months.
The ComfortScan appears to be a machine using optical technology with LEDs to detect angiogenesis in breast nodules and is to be used as an adjunct to mammography for the detection of malignant breast lesions. It won the
"Most Innovative Product for 2002" by NJTC. However, the
Dobi Medical website presents no clinical data. A quick
Pubmed search threw up a couple of "concept" articles, but no clinical data.
If a modality has to become clinically useful there has to be a signficant body of literature to support its use. If that modality is to be used for screening the body of literature has to be vast and time-tested. In the breast, it has to compete with mammography and contrast-enhanced breast MRI.
Even if these machines are priced equivalent to analog mammography machines, in India at least, I can't see how these machines would sell. Mammography is a difficult concept to sell...add to that another modality at a similar cost with no large clinical study to prove its utility? UTL is very brave to think that it can sell 40 such machines in the next 18 months. Moreover a
quick search of the UTL site shows that it has no background in healthcare. Wow! All the best to them.